[1] Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11(5): 615993.
[2] Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting[J]. Ocul Surf, 2013, 11(4): 246-258.
[3] Baudouin C, Cochener B, Pisella PJ, et al. Randomized, phase Ⅲ study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease[J]. Eur J Ophthalmol, 2012, 22(5): 751-761.
[4] Vogel R, Crockett RS, Oden N, et al.Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena)[J]. Am J Ophthalmol, 2010, 149(4):594-601.
[5] Coulter I, Frewin S, Krassas GE, et al. Psychological implications of Graves′ orbitopathy[J]. Eur J Endocrinol, 2007, 157(2): 127-131.
[6] Kashkouli MB, Alemzadeh SA, Aghaei H, et al. Subjective versus objective dry eye disease in patients with moderate-severe thyroid eye disease[J]. Ocul Surf, 2018, 16(4): 458-462.
[7] Nowak M, Marek B, Kos-Kudła B, et al. [Tear film profile in patients with active thyroid orbithopathy][J]. Klin Oczna, 2005, 107(7-9): 479-482.
[8] Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy[J]. Sci Rep, 2018, 8(1): 10792.
[9] Huang D, Xu N, Song Y, et al. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2012, 250(4): 619-625.
[10] Ma JYW, Sze YH, Bian JF, et al. Critical role of mass spectrometry proteomics in tear biomarker discovery for multifactorial ocular diseases (Review)[J]. Int J Mol Med, 2021, 47(5):212-232.
[11] Hsu SL, Lee PY, Chang CH, et al. Immunological impression cytology of the conjunctival epithelium in patients with thyroid orbitopathy-related dry eye[J]. Genet Mol Res, 2016, 15(3):118-132.
[12] Matheis N, Grus FH, Breitenfeld M, et al. Proteomics differentiate between thyroid-associated orbitopathy and dry eye syndrome[J]. Invest Ophthalmol Vis Sci, 2015, 56(4): 2649-2656.
[13] Rouen PA, White ML.Dry eye disease: prevalence, assessment, and management[J]. Home Healthc Now, 2018, 36(2): 74-83.
[14] Singh VK, Sharma P, Vaksh UKS, et al. Current approaches for the regeneration and reconstruction of ocular surface in dry eye[J]. Front Med (Lausanne), 2022, 9(5): 885780.
[15] Thorne AW, Rootman DB.Influence of surgical approach for decompression on lower eyelid position in thyroid eye disease[J]. Orbit, 2020, 39(2): 84-86.
[16] Kim JS, Blizzard S, Woodward JA, et al. Prostaglandin-associated periorbitopathy in children and young adults with glaucoma[J]. Ophthalmol Glaucoma, 2020, 3(4): 288-294.
[17] Chin YH, Ng CH, Lee MH, et al. Prevalence of thyroid eye disease in Graves' disease: a meta-analysis and systematic review[J]. Clin Endocrinol (Oxf), 2020, 93(4): 363-374.
[18] Lee DC, Young SM, Kim YD, et al. Course of upper eyelid retraction in thyroid eye disease[J]. Br J Ophthalmol, 2020, 104(2): 254-259.
[19] Scott AB.Injection treatment of endocrine orbital myopathy[J]. Doc Ophthalmol, 1984, 58(1): 141-145.
[20] Uddin JM, Davies PD.Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection[J]. Ophthalmology, 2002, 109(6): 1183-1187.
[21] Morgenstern KE, Evanchan J, Foster JA, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction[J]. Ophthalmic Plast Reconstr Surg, 2004, 20(3): 181-185.
[22] Hassan Hussien M, Abd El-Wahed Hassan E, El-Haddad NSEM. Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction[J]. Ther Adv Ophthalmol, 2020, 12:2515841420979113.
[23] Nava Castañeda A, Tovilla Canales JL, Garnica Hayashi L,et al.Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A[J]. J Fr Ophtalmol, 2017, 40(4):279-284.
[24] Kandasamy S, Agrawal S, Pushker N, et al. Correlation of levator-Muller's complex thickness on ultrasound biomicroscopy to botulinum toxin A injection in thyroid-related upper eyelid retraction[J]. J Ultrasound Med, 2023, 42(2): 399-408.
[25] Dawson E, Ali N, Lee JP.Botulinum toxin injection into the superior rectus for treatment of strabismus[J]. Strabismus, 2012, 20(1): 24-25.
[26] Issaho DC, Carvalho FRS, Tabuse MKU, et al.The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-analysis[J]. Invest Ophthalmol Vis Sci, 2017, 58(12): 5468-5476.
[27] Yang HK, Kim DH, Hwang JM.Botulinum toxin injection without electromyographic guidance in consecutive esotropia[J]. PLoS One, 2020, 15(11): e0241588.
[28] Young SM, Kim YD, Lang SS, et al. Transconjunctival triamcinolone injection for upper lid retraction in thyroid eye disease—a new injection method[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(6): 587-593.
[29] Xu DD, Chen Y, Xu HY, et al. Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy[J]. Int J Ophthalmol, 2018, 11(8): 1290-1295.
[30] Tu X, Dong Y, Zhang H, et al. Corticosteroids for Graves' ophthalmopathy: systematic review and meta-analysis[J]. Biomed Res Int, 2018, 18(4): 4845894.
[31] Joos ZP, Sullivan TJ.Peri-levator palpebrae superioris triamcinolone injection for the treatment of thyroid eye disease-associated upper eyelid retraction[J]. Clin Exp Ophthalmol, 2017, 45(6): 651-652.
[32] Li D, Sun F.Observations on the efficacy of two methods for the treatment of upper eyelid retraction in thyroid-associated ophthalmopathy[J]. Biomed Res Int, 2021, 1(3): 9514279.
[33] Hassan Hussien M, Abd El-Wahed Hassan E, El-Haddad N. Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction[J]. Ther Adv Ophthalmol, 2020, 12(2): 25158414-20979113.
[34] Li Q, Ye H, Ding Y, et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases[J]. PLoS One, 2017, 12(5): e0176064.
[35] Hintschich C.Eyelid surgery in Graves' orbitopathy[J]. Klin Monbl Augenheilkd, 2021, 238(1): 33-40.
[36] Henderson JW.A surgical procedure for retraction of eyelids in endocrine exophthalmos (a moving picture)[J]. Trans Am Ophthalmol Soc, 1965, 63(1): 70-74.
[37] Gildener-Leapman JR, Sheps I, Stein R, et al. The sutureless mullerectomy[J]. Ophthalmic Plast Reconstr Surg, 2019, 35(3): 290-293.
[38] Sun J, Liu X, Zhang Y, et al. Bovine acellular dermal matrix for levator lengthening in thyroid-related upper-eyelid retraction[J]. Med Sci Monit, 2018, 4(2): 2728-2734.
[39] Lee J, Lee H, Park M, et al. Modified full thickness graded blepharotomy for upper eyelid retraction associated with thyroid eye disease in East Asians[J]. Ann Plast Surg, 2016, 77(6): 592-596.
[40] Vasanthapuram VH, Naik MN.Blepharoptosis in thyroid eye disease: etiopathogenesis, clinical features and correlation with thyroid eye disease[J]. Int Ophthalmol, 2022, 42(1): 13-18.
[41] Brogan K, Farrugia ME, Crofts K.Ptosis surgery in patients with myasthenia gravis: a useful adjunct to medical therapy[J]. Semin Ophthalmol, 2018, 33(3): 429-434.
